|Title:||Morpholine and thiomorpholine tachykinin receptor antagonists|
|Abstract:||Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis, and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.|
|Inventor(s):||Dorn; Conrad P. (Plainfield, NJ), Finke; Paul E. (Milltown, NJ), Hale; Jeffrey J. (Westfield, NJ), MacCoss; Malcolm (Freehold, NJ), Mills; Sander G. (Woodbridge, NJ), Shah; Shrenik K. (Metuchen, NJ), Chambers; Mark Stuart (North Bushey, GB2), Harrison; Timothy (Great Dunmow, GB2), Ladduwahetty; Tamara (Buckhurst Hill, GB2), Williams; Brian John (Great Dunnow, GB2)|
|Assignee:||Merck & Co., Inc. (Rahway, NJ)|
Patent Claim Types:|
see list of patent claims
|Compound; Composition; Use; Process;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|European Patent Office||0734381||► subscribe||04C0010||France||► subscribe|
|European Patent Office||0734381||► subscribe||3/2004||Austria||► subscribe|
|European Patent Office||0734381||► subscribe||300146||Netherlands||► subscribe|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.